Spexin – Kodiac biolabs

Our opinion on this compoundNovel, promising

58/100

Endogenous GALR2/GALR3-selective neuropeptide with compelling metabolic biomarker signal and zero human interventional data

Look, spexin is one of those compounds that deserves more attention than it gets. Identified in 2007 via hidden Markov model screening of the human proteome, it spent years as a bioinformatic curiosity before anyone worked out what it actually does. What we now know is genuinely interesting: it’s a 14-amino-acid amidated peptide that selectively activates GALR2 and GALR3 at nanomolar potency while leaving GALR1 completely cold. That receptor selectivity profile is the whole story here, because galanin itself hits all three subtypes and nobody has had a clean endogenous tool for dissecting GALR2/GALR3-specific biology until spexin showed up.

The mechanism picture is wide. Spexin suppresses food intake through hypothalamic regulation of NPY, AgRP, POMC, and CART. It inhibits long-chain fatty acid uptake in adipocytes. It interacts with leptin signaling. The analog LIT-01-144 produces non-opioid peripheral antinociception through GALR2 in inflammatory pain models, which is an angle that we think is genuinely worth bench time given the current state of opioid-alternative research. Theres also anxiolytic activity in murine behavioral models and suppression of LH/FSH through GALR2/GALR3 in the reproductive axis. Multi-domain doesn’t begin to cover it.

The human biomarker story is where spexin becomes clinically plausible. Circulating spexin is consistently reduced in obesity, type 1 diabetes, type 2 diabetes, metabolic syndrome, and PCOS across independent cohorts from multiple research groups. That kind of cross-condition downregulation pattern is a signal worth taking seriously, even if it doesn’t tell you whether low spexin is cause or consequence. What it does tell you is that the endogenous system is physiologically relevant to conditions people actually care about.

Here’s the thing though: no interventional human data exists. None. The entire clinical story is associative biomarker work. That’s not a fatal flaw for a research compound, but it means the translational arrow is pointing in a promising direction rather than landing anywhere confirmed. The preclinical base is solid and multi-lab across multiple species, which puts it clearly above BPC-157 territory, but the absence of any phase 1 safety or pharmacokinetic data in humans is a real gap that limits how confidently you can extrapolate the rodent findings.

What we like most here is the probe value. If your program touches GALR2/GALR3 biology, appetite circuitry, non-opioid analgesia mechanisms, or the metabolic neuroendocrine axis, spexin is the cleanest endogenous tool available for that receptor pair. The analog development literature (LIT-01-144 and related dN1-Qu derivatives) gives investigators metabolically stabilized scaffolds to work with, which extends the utility considerably beyond native peptide stability limits. Scoring this one at 58, mostly held back by the human data gap and a translational signal that’s associative rather than interventional.

Novelty: 65
Mechanism promise: 68
In-category differentiation: 65
Evidence quality: 42
Translational signal: 35
Research bench value: 65

Rationale Spexin scores well on novelty and differentiation because it is the only known natural GALR2/GALR3-selective agonist, giving it genuine probe value that galanin itself cannot provide, but the complete absence of interventional human trials and reliance on associative biomarker data drags translational and evidence scores into the 35-42 range, pulling the overall into the high-50s.

Endogenous neuropeptide agonist of galanin receptor type 2 (GALR2) and galanin receptor type 3 (GALR3)

A 14-amino-acid C-terminally amidated neuropeptide of the galanin/kisspeptin/spexin superfamily, identified by bioinformatic hidden Markov model screening of the human proteome in 2007 and subsequently characterized as a satiety factor, metabolic regulator, anxiolytic peptide, and antinociceptive agent operating through selective activation of galanin receptor subtypes 2 and 3.

Abstract

Spexin (SPX), also designated neuropeptide Q (NPQ), is a 14-amino-acid peptide hormone encoded by the C12orf39 gene on human chromosome 12 and processed from a 116-amino-acid prepropeptide by dibasic cleavage and C-terminal alpha-amidation [1, 2]. The mature human sequence (NWTPQAMLYLKGAQ-NH2) is perfectly conserved across all mammalian species examined and differs by only one to two residues from teleost orthologs, placing spexin among the most evolutionarily conserved vertebrate peptide hormones [3]. First identified in 2007 by Mirabeau and colleagues through a hidden Markov model algorithm designed to detect novel secreted peptide hormones in the human genome, and first confirmed biochemically in murine esophageal and gastric tissue [1], spexin was subsequently shown to activate galanin receptor type 2 (GALR2) and galanin receptor type 3 (GALR3) with nanomolar potency (EC50 values of approximately 45.7 and 112.2 nM respectively) while showing no measurable activity at galanin receptor type 1 (GALR1) [4, 5]. This receptor selectivity profile distinguishes spexin from galanin itself, which activates all three galanin receptor subtypes, and establishes spexin as a naturally occurring GALR2/GALR3-selective agonist. The peptide is expressed broadly across central and peripheral tissues including the hypothalamus, hippocampus, amygdala, adipose tissue, liver, gastrointestinal tract, pancreas, kidney, heart, ovary, and testis [6, 7]. Functionally, spexin has been characterized as a satiety factor that suppresses food intake in goldfish, zebrafish, and mice through hypothalamic regulation of orexigenic (neuropeptide Y, agouti-related protein) and anorexigenic (proopiomelanocortin, cocaine- and amphetamine-regulated transcript) neuropeptides [8, 9, 10]. In adipose tissue, spexin inhibits long-chain fatty acid uptake into adipocytes and promotes weight loss in diet-induced obese rodents [11]. Circulating spexin concentrations are significantly reduced in human obesity, type 1 diabetes, type 2 diabetes, metabolic syndrome, and polycystic ovary syndrome, establishing the peptide as a candidate biomarker for metabolic dysregulation [12, 13, 14]. Beyond metabolic regulation, spexin-based GALR2-selective agonists produce anxiolytic effects in murine behavioral models [5], and the metabolically stabilized analog LIT-01-144 produces potent non-opioid peripheral antinociception in persistent inflammatory pain through GALR2 activation [15]. In reproductive physiology, spexin inhibits gonadotropin (LH and FSH) synthesis and secretion in multiple vertebrate species and negatively regulates ovarian steroidogenesis [16, 17]. No human clinical trials of exogenous spexin administration have been reported; the compound remains in the preclinical and biomarker research phase. This monograph reviews the chemistry, gene structure, and peptide processing of spexin; the receptor pharmacology and signal transduction through GALR2 and GALR3; the preclinical pharmacology across metabolic, appetite, nociceptive, anxiolytic, reproductive, and cardiovascular domains; the human biomarker and associative clinical evidence; sourcing and handling considerations for research-grade material; analog development for metabolic stability; and a comparative assessment against five related peptide or receptor-targeted candidates on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1387Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.